Trial Profile
A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Jul 2022 Results published in the Thyroid
- 07 Jun 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.